Qiagen Shares Rise on Buyout Interest Reports

By EC Assets · Published 17 September 2026

Qiagen stock jumped following reports of potential buyout interest. Buyout firms including EQT AB, Advent, and KKR are exploring a takeover of the diagnostics company. Bloomberg News reported this early takeover interest. Qiagen operates as a molecular diagnostics and life-science tools platform. The company offers products such as QuantiFERON, QIAstat-Dx, QIAcuity dPCR, and QDI bioinformatics. Renewed takeover speculation has focused on Qiagen. KKR has been active, with its valuation in focus after its interest in Qiagen and the launch of Allyntra. This article is intended for informational purposes only. It does not constitute investment advice.